WuXi Biologics To Be ‘World’s No.1’ Biologics Maker
Executive Summary
WuXi Biologics is aiming high to become the world’s biggest biologics manufacturer within five years after seeing strong confidence from capital markets in its growth potential and a boost from its new biologics manufacturing facility. The Chinese company plans on more investment in early 2018 to prepare for an expected biologics surge in China, its chief executive tells Scrip.
You may also be interested in...
Asia Attracts Manufacturing Capital As Companies Eye Expanding Needs
Life science and pharma companies have been actively investing in Asia over the past month as they look to increase regional manufacturing capacities to tap into burgeoning markets and meet rising demand for new technologies, biologics and high-quality products, while Chinese firms have also been expanding their international presence.
WuXi To Lead ‘China First’ Strategy For Lilly’s Novel Cholesterol Drug
Following the announcement of a strategic partnership last year, WuXi AppTec and Eli Lilly have now finished toxicology studies for the world’s first small molecule drug to target low-density lipoprotein cholesterol and triglycerides, and are aiming for a China-first approval under a global simultaneous development program.
Beigene/Boehringer Biomanufacturing Bond Tests China MAH System
Nasdaq-listed BeiGene expects to need more CMO services for its clinical stage biologics following on from a clinical trials manufacturing agreement for a PD-1 antibody with Boehringer Ingelheim China, which marked the first such pilot program under China’s drug marketing authorization holder system. Shanghai is also preparing risk guarantee funds to back the pilot program, in order to promote pharmaceutical innovation.